Upsher-Smith Laboratories has acquired the US rights to Tosymra sumatriptan nasal spray from Dr. Reddy's Laboratories, the companies have announced. The FDA approved Dr. Reddy's subsidiary Promius Pharma's NDA for Tosymra in January 2019. The agreement, which also covered US rights to Zembrace Symtouch sumatriptan injection, included a $70 million upfront payment, … [Read more...] about Upsher-Smith acquires US rights to Tosymra sumatriptan nasal spray
Business
Insys Therapeutics files for bankruptcy, plans to sell all assets
Insys Therapeutics has filed for Chapter 11 bankruptcy and plans to sell "substantially all of the company’s assets," the company said. Insys's pipeline includes inhaled dronabinol, intranasal epinephrine, and intranasal naloxone. NDA submissions for the nasal sprays had been planned for 2019. The bankruptcy filing comes in the wake of legal troubles related to … [Read more...] about Insys Therapeutics files for bankruptcy, plans to sell all assets
Mundipharma gets Australian rights to Penthrox
Medical Developments International (MVP) announced that Mundipharma has acquired exclusive Australian distribution rights for the Penthrox methoxyflurane inhaler. Mundipharma already has the rights to market Penthrox in most of Europe. Mundipharma Australia and New Zealand Managing Director Jane Orr, commented, “Options for pain relief are limited in many clinical … [Read more...] about Mundipharma gets Australian rights to Penthrox
Kurve Technology gets Defense Department contract for intranasal therapy for traumatic brain injury
Nasal drug delivery specialist Kurve Technology announced that the US Department of Defense (DoD) has awarded the company a contract for testing a formulation for the treatment of traumatic brain injury (TBI). The Kurve ViaNase device is an electronic atomizer based on a controlled particle dispersion technology platform making use of vortical flow that … [Read more...] about Kurve Technology gets Defense Department contract for intranasal therapy for traumatic brain injury
TFF Pharmaceuticals raises over $8 million, announces executive appointments
DPI developer TFF Pharmaceuticals said that is has raised $8.17 million through a Series A preferred stock offering and that it will use the funds for R&D. In April 2018, the company announced that it had raised $14 million for development of inhaled drugs, also through a Series A preferred stock offering. In the past year, TFF has received patents in the … [Read more...] about TFF Pharmaceuticals raises over $8 million, announces executive appointments
Acerus Pharmaceuticals licenses intranasal testosterone technology from UT Austin
Acerus Pharmaceuticals said that it has acquired exclusive worldwide rights to technology related to intranasal delivery of testosterone from the University of Texas at Austin. The company said that the agreement covers the use of the intranasal testosterone technology "in all applicable fields." Formerly known as Trimel, Acerus previously developed Natesto … [Read more...] about Acerus Pharmaceuticals licenses intranasal testosterone technology from UT Austin
BlueWillow announces US patent for intranasal anthrax vaccine
According to BlueWillow Biologics, the University of Michigan has been issued US patent No. 10,138,279 which covers an intranasal anthrax vaccine formulated with BlueWillow's NanoVax adjuvant. BlueWillow (formerly NanoBio) is a spin out from the University of Michigan and has an exclusive license to the anthrax vaccine. The company said that its partner … [Read more...] about BlueWillow announces US patent for intranasal anthrax vaccine
Insmed raises $250 million in public stock offering
Insmed Incorporated said that a just-closed public stock offering generated net proceeds of about $235.5 million that will be used for continuing commercialization of Arikayce amikacin liposome inhalation suspension (ALIS). The offering of 9,615,385 shares of common stock at $26.00/share resulted in gross proceeds of about $250 million. The underwriters of the … [Read more...] about Insmed raises $250 million in public stock offering
According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
Vectura Group and Sosei Group each said that they are owed $2.5 million milestone payments from Novartis after the EU accepted Novartis's MAA for its QVM149 indacaterol/glycopyrronium/mometasone furoate DPI for the treatment of asthma that is inadequately controlled. Vectura said that approval of the MAA would trigger an additional milestone payment of $5 million. … [Read more...] about According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
AMSL Diabetes to distribute Afrezza inhaled insulin in Australia
MannKind Corporation has announced that signed a marketing and distribution agreement with Australasian Medical & Scientific Ltd division AMSL Diabetes for commercialization of Afrezza inhaled insulin in Australia. AMSL Diabetes will take responsibility for getting Australian regulatory and reimbursement approval for Afrezza and for sales, marketing, and … [Read more...] about AMSL Diabetes to distribute Afrezza inhaled insulin in Australia